Affiliation:
1. MRC Centre for Molecular Bacteriology and Infection, Imperial College London, London, United Kingdom
Abstract
Co-trimoxazole (SXT) is a combination therapeutic that consists of sulfamethoxazole and trimethoprim that is increasingly used to treat skin and soft tissue infections caused by methicillin-resistant
Staphylococcus aureus
(MRSA). However, the use of SXT is limited to the treatment of low-burden, superficial
S. aureus
infections and its therapeutic value is compromised by the frequent emergence of resistance.
Funder
Shionogi
UK Research and Innovation | Medical Research Council
NIHR Imperial Biomedical Research Centre
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献